Emerging molecular target antagonists for the treatment of biliary tract cancer

Pasquale Lombardi, Donatella Marino, Elisabetta Fenocchio, Giovanna Chilà, Massimo Aglietta, Francesco Leone

Research output: Contribution to journalReview article

Abstract

Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and improving clinical outcomes. Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be reviewed. Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted treatments under evaluation. In addition, innovative trial design will allow to offer a chance for tailored medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their histology.

Original languageEnglish
Pages (from-to)63-75
Number of pages13
JournalExpert Opinion on Emerging Drugs
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2 2018

Fingerprint

Biliary Tract Neoplasms
gemcitabine
Clinical Trials
Therapeutics
Mutation
Expert Testimony
Immunotherapy
Cisplatin
Histology
Biomarkers
Medicine
Recurrence
Incidence
Neoplasms

Keywords

  • Biliary tract cancer
  • cholangiocarcinoma
  • emerging drugs
  • FGFR
  • growth factor receptor
  • IDH1
  • immunotherapy
  • molecular targeted drugs

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging molecular target antagonists for the treatment of biliary tract cancer. / Lombardi, Pasquale; Marino, Donatella; Fenocchio, Elisabetta; Chilà, Giovanna; Aglietta, Massimo; Leone, Francesco.

In: Expert Opinion on Emerging Drugs, Vol. 23, No. 1, 02.01.2018, p. 63-75.

Research output: Contribution to journalReview article

Lombardi, Pasquale ; Marino, Donatella ; Fenocchio, Elisabetta ; Chilà, Giovanna ; Aglietta, Massimo ; Leone, Francesco. / Emerging molecular target antagonists for the treatment of biliary tract cancer. In: Expert Opinion on Emerging Drugs. 2018 ; Vol. 23, No. 1. pp. 63-75.
@article{594d6db1508043da9f83c0833f347405,
title = "Emerging molecular target antagonists for the treatment of biliary tract cancer",
abstract = "Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and improving clinical outcomes. Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be reviewed. Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted treatments under evaluation. In addition, innovative trial design will allow to offer a chance for tailored medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their histology.",
keywords = "Biliary tract cancer, cholangiocarcinoma, emerging drugs, FGFR, growth factor receptor, IDH1, immunotherapy, molecular targeted drugs",
author = "Pasquale Lombardi and Donatella Marino and Elisabetta Fenocchio and Giovanna Chil{\`a} and Massimo Aglietta and Francesco Leone",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/14728214.2018.1444749",
language = "English",
volume = "23",
pages = "63--75",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Emerging molecular target antagonists for the treatment of biliary tract cancer

AU - Lombardi, Pasquale

AU - Marino, Donatella

AU - Fenocchio, Elisabetta

AU - Chilà, Giovanna

AU - Aglietta, Massimo

AU - Leone, Francesco

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and improving clinical outcomes. Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be reviewed. Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted treatments under evaluation. In addition, innovative trial design will allow to offer a chance for tailored medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their histology.

AB - Introduction: Biliary tract cancers (BTCs) are a heterogeneous group of cancers, characterized by low incidence but poor prognosis. Even after complete surgical resection for early stage, relapse is frequent and the lack of effective treatments contributes to the dismal prognosis. To date, the only standard treatment in first-line is cisplatin/gemcitabine combination, whereas no standard in 2nd-line has been defined. Hence, the current goal is to better understand the biology of BTCs, discovering new treatment methods and improving clinical outcomes. Areas covered: The development of next-generation-sequencing has unveiled the picture of the molecular signatures characterizing BTCs, leading to the identification of actionable mutations in biomarker-driven clinical trials. In this review we will cover the genetic landscape of BTC, focusing on the efficacy of existing treatments. Furthermore, we will discuss emerging molecular targets and evaluate the findings of pre-clinical studies. Finally, the encouraging results of clinical trials involving targeted therapies or immunotherapy will be reviewed. Expert opinion: FGFR fusion rearrangements and IDH1 or IDH2 mutations are the most promising targeted treatments under evaluation. In addition, innovative trial design will allow to offer a chance for tailored medicine to infrequent subgroups of BTCs patients based on their molecular features rather than their histology.

KW - Biliary tract cancer

KW - cholangiocarcinoma

KW - emerging drugs

KW - FGFR

KW - growth factor receptor

KW - IDH1

KW - immunotherapy

KW - molecular targeted drugs

UR - http://www.scopus.com/inward/record.url?scp=85043982470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043982470&partnerID=8YFLogxK

U2 - 10.1080/14728214.2018.1444749

DO - 10.1080/14728214.2018.1444749

M3 - Review article

C2 - 29468924

AN - SCOPUS:85043982470

VL - 23

SP - 63

EP - 75

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -